FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008739925> ?p ?o ?g. }

• W3008739925 endingPage "2563.e3" @default.
• W3008739925 startingPage "2554" @default.
• W3008739925 abstract "Background & AimsLittle is known about how a sustained virologic response (SVR) to treatment of hepatitis C virus infection with direct-acting antivirals (DAAs) affects patient mortality and development of new liver-related events. We aimed to evaluate the incidence of disease progression in patients treated with DAAs.MethodsWe performed a prospective multicenter cohort study of 1760 patients who received DAA treatment at 23 hospitals in Latin America, from May 1, 2016, through November 21, 2019. We excluded patients with a history of liver decompensation, hepatocellular carcinoma (HCC), or solid-organ transplantation. Disease progression after initiation of DAA therapy included any of the following new events: liver decompensation, HCC, liver transplantation, or death. Evaluation of variables associated with the primary outcome was conducted using a time-dependent Cox proportional hazards models.ResultsDuring a median follow-up period of 26.2 months (interquartile range, 15.3–37.5 mo), the overall cumulative incidence of disease progression was 4.1% (95% CI, 3.2%–5.1%), and after SVR assessment was 3.6% (95% CI, 2.7%–4.7%). Baseline variables associated with disease progression were advanced liver fibrosis (hazard ratio [HR], 3.4; 95% CI, 1.2–9.6), clinically significant portal hypertension (HR, 2.1; 95% CI, 1.2–3.8), and level of albumin less than 3.5 mg/dL (HR, 4.1; 95% CI, 2.3–7.6), adjusted for SVR achievement as a time covariable. Attaining an SVR reduced the risk of liver decompensation (HR, 0.3; 95% CI, 0.1–0.8; P = .016) and de novo HCC (HR, 0.2; 95% CI, 0.1%–0.8%; P = .02) in the overall cohort.ConclusionsTreatment of hepatitis C virus infection with DAAs significantly reduces the risk of new liver-related complications and should be offered to all patients, regardless of disease stage. Clinicaltrials.gov: NCT03775798. Little is known about how a sustained virologic response (SVR) to treatment of hepatitis C virus infection with direct-acting antivirals (DAAs) affects patient mortality and development of new liver-related events. We aimed to evaluate the incidence of disease progression in patients treated with DAAs. We performed a prospective multicenter cohort study of 1760 patients who received DAA treatment at 23 hospitals in Latin America, from May 1, 2016, through November 21, 2019. We excluded patients with a history of liver decompensation, hepatocellular carcinoma (HCC), or solid-organ transplantation. Disease progression after initiation of DAA therapy included any of the following new events: liver decompensation, HCC, liver transplantation, or death. Evaluation of variables associated with the primary outcome was conducted using a time-dependent Cox proportional hazards models. During a median follow-up period of 26.2 months (interquartile range, 15.3–37.5 mo), the overall cumulative incidence of disease progression was 4.1% (95% CI, 3.2%–5.1%), and after SVR assessment was 3.6% (95% CI, 2.7%–4.7%). Baseline variables associated with disease progression were advanced liver fibrosis (hazard ratio [HR], 3.4; 95% CI, 1.2–9.6), clinically significant portal hypertension (HR, 2.1; 95% CI, 1.2–3.8), and level of albumin less than 3.5 mg/dL (HR, 4.1; 95% CI, 2.3–7.6), adjusted for SVR achievement as a time covariable. Attaining an SVR reduced the risk of liver decompensation (HR, 0.3; 95% CI, 0.1–0.8; P = .016) and de novo HCC (HR, 0.2; 95% CI, 0.1%–0.8%; P = .02) in the overall cohort. Treatment of hepatitis C virus infection with DAAs significantly reduces the risk of new liver-related complications and should be offered to all patients, regardless of disease stage. Clinicaltrials.gov: NCT03775798." @default.
• W3008739925 created "2020-03-06" @default.
• W3008739925 creator A5001592155 @default.
• W3008739925 creator A5002492281 @default.
• W3008739925 creator A5003424521 @default.
• W3008739925 creator A5006023542 @default.
• W3008739925 creator A5009143997 @default.
• W3008739925 creator A5011620450 @default.
• W3008739925 creator A5012666865 @default.
• W3008739925 creator A5018972895 @default.
• W3008739925 creator A5021496172 @default.
• W3008739925 creator A5023129910 @default.
• W3008739925 creator A5031678520 @default.
• W3008739925 creator A5032277083 @default.
• W3008739925 creator A5034649940 @default.
• W3008739925 creator A5037478920 @default.
• W3008739925 creator A5038516591 @default.
• W3008739925 creator A5040880879 @default.
• W3008739925 creator A5042335593 @default.
• W3008739925 creator A5042824385 @default.
• W3008739925 creator A5046804207 @default.
• W3008739925 creator A5053037887 @default.
• W3008739925 creator A5058331826 @default.
• W3008739925 creator A5060249476 @default.
• W3008739925 creator A5060819911 @default.
• W3008739925 creator A5062669313 @default.
• W3008739925 creator A5063105386 @default.
• W3008739925 creator A5067144664 @default.
• W3008739925 creator A5072574591 @default.
• W3008739925 creator A5074630626 @default.
• W3008739925 creator A5078060269 @default.
• W3008739925 creator A5080516718 @default.
• W3008739925 creator A5084831508 @default.
• W3008739925 creator A5086484270 @default.
• W3008739925 creator A5089493567 @default.
• W3008739925 date "2020-10-01" @default.
• W3008739925 modified "2023-10-17" @default.
• W3008739925 title "Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents" @default.
• W3008739925 cites W2042158802 @default.
• W3008739925 cites W2058200448 @default.
• W3008739925 cites W216121951 @default.
• W3008739925 cites W2275737843 @default.
• W3008739925 cites W2332315868 @default.
• W3008739925 cites W2472585716 @default.
• W3008739925 cites W2514140875 @default.
• W3008739925 cites W2519498039 @default.
• W3008739925 cites W2536609598 @default.
• W3008739925 cites W2582878252 @default.
• W3008739925 cites W2739110955 @default.
• W3008739925 cites W2785166541 @default.
• W3008739925 cites W2790712383 @default.
• W3008739925 cites W2802906787 @default.
• W3008739925 cites W2889932786 @default.
• W3008739925 cites W2909374928 @default.
• W3008739925 cites W2909795031 @default.
• W3008739925 cites W2912626533 @default.
• W3008739925 cites W2913125611 @default.
• W3008739925 cites W2947887865 @default.
• W3008739925 doi "https://doi.org/10.1016/j.cgh.2020.02.044" @default.
• W3008739925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32113892" @default.
• W3008739925 hasPublicationYear "2020" @default.
• W3008739925 type Work @default.
• W3008739925 sameAs 3008739925 @default.
• W3008739925 citedByCount "41" @default.
• W3008739925 countsByYear W30087399252020 @default.
• W3008739925 countsByYear W30087399252021 @default.
• W3008739925 countsByYear W30087399252022 @default.
• W3008739925 countsByYear W30087399252023 @default.
• W3008739925 crossrefType "journal-article" @default.
• W3008739925 hasAuthorship W3008739925A5001592155 @default.
• W3008739925 hasAuthorship W3008739925A5002492281 @default.
• W3008739925 hasAuthorship W3008739925A5003424521 @default.
• W3008739925 hasAuthorship W3008739925A5006023542 @default.
• W3008739925 hasAuthorship W3008739925A5009143997 @default.
• W3008739925 hasAuthorship W3008739925A5011620450 @default.
• W3008739925 hasAuthorship W3008739925A5012666865 @default.
• W3008739925 hasAuthorship W3008739925A5018972895 @default.
• W3008739925 hasAuthorship W3008739925A5021496172 @default.
• W3008739925 hasAuthorship W3008739925A5023129910 @default.
• W3008739925 hasAuthorship W3008739925A5031678520 @default.
• W3008739925 hasAuthorship W3008739925A5032277083 @default.
• W3008739925 hasAuthorship W3008739925A5034649940 @default.
• W3008739925 hasAuthorship W3008739925A5037478920 @default.
• W3008739925 hasAuthorship W3008739925A5038516591 @default.
• W3008739925 hasAuthorship W3008739925A5040880879 @default.
• W3008739925 hasAuthorship W3008739925A5042335593 @default.
• W3008739925 hasAuthorship W3008739925A5042824385 @default.
• W3008739925 hasAuthorship W3008739925A5046804207 @default.
• W3008739925 hasAuthorship W3008739925A5053037887 @default.
• W3008739925 hasAuthorship W3008739925A5058331826 @default.
• W3008739925 hasAuthorship W3008739925A5060249476 @default.
• W3008739925 hasAuthorship W3008739925A5060819911 @default.
• W3008739925 hasAuthorship W3008739925A5062669313 @default.
• W3008739925 hasAuthorship W3008739925A5063105386 @default.
• W3008739925 hasAuthorship W3008739925A5067144664 @default.
• W3008739925 hasAuthorship W3008739925A5072574591 @default.
• W3008739925 hasAuthorship W3008739925A5074630626 @default.
• W3008739925 hasAuthorship W3008739925A5078060269 @default.

• next